Is Micron a Good Stock to Buy Now?
Like most of its peers in the semiconductor industry, Micron…
Sell
15
ENTA Quote, Financials, Valuation and Earnings
Last price:
$4.94
Seasonality move
:
-2.51%
Day range:
$4.73 - $5.11
52-week range:
$4.09 - $17.24
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.57x
P/B ratio:
0.94x
Volume:
358.2K
Avg. volume:
265.9K
1-year change:
-67.9%
Market cap:
$105.2M
Revenue:
$67.6M
EPS (TTM):
-$4.95
Analysts' Opinion
-
Consensus RatingEnanta Pharmaceuticals has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $15.14, Enanta Pharmaceuticals has an estimated upside of 207.16% from its current price of $4.93.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $4.93.
Fair Value
-
According to the consensus of 4 analysts, Enanta Pharmaceuticals has 207.16% upside to fair value with a price target of $15.14 per share.
ENTA vs. S&P 500
-
Over the past 5 trading days, Enanta Pharmaceuticals has overperformed the S&P 500 by 11.38% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Enanta Pharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Enanta Pharmaceuticals revenues have been falling on a year-over-year basis for 14 quarters in a row. In the most recent quarter Enanta Pharmaceuticals reported revenues of $17M.
Earnings Growth
-
Enanta Pharmaceuticals earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Enanta Pharmaceuticals reported earnings per share of -$1.05.
Enterprise value:
-111.5M
EV / Invested capital:
--
Price / LTM sales:
1.57x
EV / EBIT:
--
EV / Revenue:
-1.67x
PEG ratio (5yr expected):
-0.50x
EV / Free cash flow:
1.16x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-26.68%
Net Income Margin (TTM):
-157.57%
Return On Equity:
-70.18%
Return On Invested Capital:
-70.18%
Operating Margin:
-138.82%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $82.1M | $73.6M | $66.6M | $18M | $17M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$123.4M | -$142.1M | -$110.3M | -$34.9M | -$23.5M | |
| EBITDA | -$118.6M | -$124.9M | -$94.4M | -$29.9M | -$19.9M | |
| Diluted EPS | -$5.82 | -$6.56 | -$4.95 | -$1.58 | -$1.05 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $445.9M | $327M | $283.7M | $390.3M | $268.1M | |
| Total Assets | $481M | $440.6M | $347.5M | $428.5M | $348.6M | |
| Current Liabilities | $23M | $37.9M | $23M | $62.4M | $49.1M | |
| Total Liabilities | $29M | $56.2M | $46.7M | $236.6M | $236.8M | |
| Total Equity | $452M | $384.4M | $300.8M | $191.9M | $111.8M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$107.2M | -$92.5M | -$70.6M | -$25M | -$16.8M | |
| Cash From Investing | $43M | -$100.3M | $140.3M | -$13.1M | $68.9M | |
| Cash From Financing | $10.7M | $190.5M | -$25.3M | -$7.4M | -$5M | |
| Free Cash Flow | -$112.1M | -$99.2M | -$96.5M | -$25.8M | -$25.5M | |
ENTA
Sector
Market Cap
$105.2M
$35M
Price % of 52-Week High
28.61%
41.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.91%
1-Year Price Total Return
-67.9%
-43.29%
Beta (5-Year)
0.692
0.743
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$4.70
200-day SMA
Sell
Level
$9.45
Bollinger Bands (100)
Sell
Level
4.97 - 7.83
Chaikin Money Flow
Buy
Level
433.3K
20-day SMA
Sell
Level
$5.29
Relative Strength Index (RSI14)
Sell
Level
39.90
ADX Line
Sell
Level
41.01
Williams %R
Neutral
Level
-52.809
50-day SMA
Sell
Level
$6.19
MACD (12, 26)
Buy
Level
0.77
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Sell
Level
-2.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.6537)
Sell
CA Score
(Annual)
Level (-1.9553)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (2.6982)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Stock Forecast FAQ
In the current month, ENTA has received 2 Buy ratings 2 Hold ratings, and 0 Sell ratings. The ENTA average analyst price target in the past 3 months is $15.14.
-
Where Will Enanta Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Enanta Pharmaceuticals share price will rise to $15.14 per share over the next 12 months.
-
What Do Analysts Say About Enanta Pharmaceuticals?
Analysts are divided on their view about Enanta Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Enanta Pharmaceuticals is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is Enanta Pharmaceuticals's Price Target?
The price target for Enanta Pharmaceuticals over the next 1-year time period is forecast to be $15.14 according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is ENTA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Enanta Pharmaceuticals is a Leans Bullish. 2 of 4 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of ENTA?
You can purchase shares of Enanta Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Enanta Pharmaceuticals shares.
-
What Is The Enanta Pharmaceuticals Share Price Today?
Enanta Pharmaceuticals was last trading at $4.94 per share. This represents the most recent stock quote for Enanta Pharmaceuticals. Yesterday, Enanta Pharmaceuticals closed at $4.93 per share.
-
How To Buy Enanta Pharmaceuticals Stock Online?
In order to purchase Enanta Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Uber Finally on the Path to Consistent Profitability?
After posting massive losses quarter after quarter for years, Uber…
How High Will MSTY Go By 2030?
YieldMax’s MSTR Option Income Strategy ETF (MSTY) is a high-yield…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 31x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.5T
P/E Ratio: 36x
Alerts
Sell
25
BULZ alert for Apr 17
MicroSectors Solactive FANG & Innov 3X Levd ETN [BULZ] is down 10.95% over the past day.
Sell
50
IBKR alert for Apr 17
Interactive Brokers Group [IBKR] is down 8.97% over the past day.
Sell
39
FNGA alert for Apr 17
MicroSectors FANG+ Index 3X Leveraged ETN [FNGA] is down 9.37% over the past day.
